Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hirosaki University to Test StemRIM’s Redasemtide for Knee Osteoarthritis
December 2, 2020
- Sosei Licenses CGRP Antagonists to Biohaven
December 2, 2020
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- Takeda Closes Sale of 18 Non-Core Meds to Celltrion in Asia-Pacific
December 2, 2020
- 1st Patient Enrolled in Adoptive Trial by Amgen, Takeda, UCB: COVID R&D Alliance
December 2, 2020
- Sanofi Japan to Sharpen Focus on Priority Pipelines as It Eyes Turnaround after 2022: President
December 1, 2020
- AstraZeneca Japan Exec Vows Thorough Safety Evaluation for COVID-19 Vaccine
December 1, 2020
- Demand for Nesp Biosimilars Spiking as Hospitals Turn to Cheaper Meds in Dialysis Care, Shipment Control Triggered
December 1, 2020
- Abbott Japan Taps Managing Exec Officer Takechi as New President
December 1, 2020
- Keytruda-Chemo Combo Filed for 1st Line Esophageal Cancer in Japan
December 1, 2020
- Chugai Now Takes Nissan Chemical to Court over Edirol Patent, Seeks Damages from Sawai, Nichi-Iko Too
November 30, 2020
- Jardiance Filed for Chronic Heart Failure in Japan: BI/Lilly
November 30, 2020
- Sales Rep Promotions Up in All Channels in September: Intage
November 30, 2020
- Takeda Seeks Japan Nod for Zejula Tablet Form
November 27, 2020
- COVID-19 Pandemic Could Have Negative Impact of Up to 170 Billion Yen on Japan Drug Market in FY2020: IQVIA
November 27, 2020
- Relugolix Nets Positive PIII Data in Endometriosis, ASKA Set to Seek Add’l Use in H1 2021
November 26, 2020
- Vibegron Fails in US PII Trial for IBS Pain: Urovant
November 26, 2020
- Shionogi, Nagasaki Univ., Kitasato Institute Join Forces on Antimalarial Drug Research
November 26, 2020
- Dupixent Auto-Injector Now Available: Sanofi
November 26, 2020
- Nippon Shinyaku Files Uptravi for CTEPH
November 26, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…